Depression and HIV/AIDS

Current Psychiatry Reports

Volumn 10, Issue 3, 2008, Pages 280-285

  Benton, Tami D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; DESIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; INDINAVIR; METHYLPHENIDATE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PEMOLINE; PLACEBO; PRASTERONE; PROTEINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TESTOSTERONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGITATION; ANTICHOLINERGIC SYNDROME; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; IRRITABILITY; LIVER TOXICITY; MORTALITY; PANIC; PREVALENCE; PROGNOSIS; PSYCHOTHERAPY; RISK FACTOR; SIDE EFFECT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSIVE DISORDER, MAJOR; HIV INFECTIONS; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 49249112750     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-008-0045-y     Document Type: Article

References (50)

1. AIDS Epidemic Update: December 2004. Joint United Nations Programme on HIV/AIDS. Geneva: World Health Organization; 2004.
2. Centers for Disease Control and Prevention: HIV/AIDS: Surveillance Report 2003, vol 15. Centers for Disease Control and Prevention website. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2003: 1-46. http://www.cdc.gov./hiv/topics/surveillance/resources/reports. Accessed April 10, 2008.
3. Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report 1998, vol 10, no 2. Centers for Disease Control and Prevention website. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 1998:1-43. www.cdc.gov./hiv/stats/hasrlink.htm. Accessed April 10, 2008.
4. US Census Bureau: Census Brief: Women in the United States: a Profile. March 2000. US Census Bureau website. http://www.census.gov/ prod/www.abs/populatio.html. Accessed April 10, 2008.
5. Centers for Disease Control and Prevention. HIV Prevention in the Third Decade. Centers for Disease Control and Prevention website. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2003. http://www.cdc.gov/hiv/resources/reports/ hiv3rddecae/index.html. Accessed April 10, 2008.
6. Anderson RN, Smith BL: Deaths: leading causes for 2001. Natl Vital Stat Rep 2003; 52:32-33, 53-54.
7. Bing EG, Burnam MA, Longshore D, et al.: Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001, 58:721-728.
8. Ciesla JA, Roberts JE: Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001, 158:725-730.
9. Morrison MF, Petitto JM, Ten Have T, et al.: Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry 2002, 159:789-796.
10. Ickovicks JR, Hamburger ME, Vlahov D, et al.: Mortality, CD4 cell count decline and depressive symptoms among HIV seropositive women. Longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001, 285:1466-1474.
11. Leserman J, Petitto JM, Gu H, et al.: Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med 2002, 32:1059-1073.
12. Burack JH, Barrett DC, Stall RD, et al.: Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA 1993, 270:2568-2573.
13. Evans DL, Leserman J, Perkins DO: Stress-associated reductions of cytotoxic T lymphocytes and natural killer cells in asymptomatic HIV infection. Am J Psychiatry 1995, 152:543-550.
14. Lyketsos CG, Hoover DR, Guccione M, et al.: Changes in depressive symptoms as AIDS develops. Am J Psychiatry 1996, 153:1430-1437.
15. Lyketsos CG, Hoover DR, Guccione M, et al.: Depressive symptoms as predictors of medical outcomes in HIV infection. JAMA 1993, 270:2563-2567.
16. Mayne TJ, Vittinghoff E, Chesney MA: Depressive affect and survival among gay and bisexual men infected with HIV. Arch Intern Med 1996, 156:2233-2238.
17. Page-Shafer K, Delorenze GN, Satariano WA: Comorbidity and survival in HIV-infected men in the San Francisco Men's Health Survey. Ann Epidemiol 1996, 6:420-430.
18. Patterson TL, Shaw WS, Semple SJ, et al.: Relationship of psychosocial factors to HIV disease progression. Ann Behav Med 1996, 18:30-39.
19. Cruess DG, Evans DL, Repetto MJ, et al.: Prevalence, diagnosis and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry 2003, 54:307-316.
20. Leserman J: HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry 2003, 54:295-306.
21. Cook JA, Grey D, Burke-Miller J, et al.: Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women. AIDS Care 2006, 18:93-100.
22. Evans DL, Charney DS, Lewis L, et al.: Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005, 58:175-189.
23. Evans DL, Staab JP, Petitto JM, et al.: Depression in the medical setting: biopsychological interactions and treatment considerations. J Clin Psychiatry 1999, 60:40-55.
24. Evans DL, Charney DS: Mood disorders and medical illness: a major public health problem. Biol Psychiatry 2003, 54:177-180.
25. Starace F, Ammassari A, Trotta P, et al.: Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002, 31(Suppl 3):S136-S139.
26. Kissane D, Clarke DM, Street AF: Demoralization syndrome: a relevant psychiatric diagnosis for palliative care. J Palliat Care 2001, 17:12-21.
27. Schade CP, Jones ER, Witten BJ: A ten year review of the validity and clinical utility of depression screening. Psychiatr Serv 1998, 49:55-61.
28. Lyketsos CG, Triesman GJ: Mood disorders in HIV infection. Psychiatr Ann 2001, 31:45-50.
29. Triesman GJ, Angelino AF, Hutton HE: Psychiatric issues in the management of patients with HIV infection. JAMA 2001, 286:2857-2864.
30. Elliot AJ, Russo J, Roy-Burne PP: The effect of changes in depression on health related quality of life (HRQol) in HIV infection. Gen Hosp Psychiatry 2002, 24:43-47.
31. Rabkin JG, Wagner GJ, Rabkin R: Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 1999, 156:101-107.
32. Grassi B, Gambini O, Garghentini, et al.: Efficacy of paroxetine for the treatment of depression in the context of HIV infection. Pharmacopsychiatry 1997, 30:70-71.
33. Ferrando SJ, Goldman JD, Charness WE: Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS: improvements in affective and somatic symptoms. Gen Hosp Psychiatry 1997, 19:89-97.
34. Ferrando SJ, Rabkin JG, de Moore GM, et al.: Antidepressant treatment for depression in HIV-seropositive women. J Clin Psychiatry 1999, 60:741-746.
35. Currier MB, Molina G, Kato M: Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study. Psychosomatics 2004, 45:210-216.
36. Schwartz JA, McDaniel JS: Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: a pilot study. Depress Anxiety 1999, 9:70-74.
37. Robinson MJ, Qaqish RB: Practical psychopharmacology in HIV-1 and acquired immunodeficiency syndrome. Psychiatr Clin North Am 2000, 25:149-175.
38. Himelhoch S, Medoff DR: Efficacy of antidepressant medication among HIV positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDS 2005, 19:813-822.
39. Rabkin JG, Rabkin R, Harrison W, et al.: Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry 1999, 156:367-372.
40. Elliot AJ, Uldall KK, Bergman K: Randomized placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry 1998, 155:367-372.
41. Markowitz JC, Kocsis JH, Fishman B, et al.: Treatment of depressive symptoms in human immunodeficiency virus positive patients. Arch Gen Psychiatry 1998, 55:452-457.
42. Elliot AJ, Russo J, Bergam K, et al.: Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. J Clin Psychiatry 1999, 60:226-231.
43. Elliot AJ, Roy-Byrne PP: Mirtazapine for depression in patients with human immunodeficiency virus [letter]. J Clin Psychopharmacol 2000, 20:265-267.
44. Currier MB, Molina G, Kato M: A prospective trial of sustained release bupropion for depression in HIV-seropositive and AIDS patients. Psychosomatics 2003, 44:120-125.
45. Wagner GJ, Rabkin JG, Rabkin R: Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res 1997, 42:407-411.
46. Wagner GJ, Rabkin R: Effects of dextroamphetamine on depression and fatigue in men with HIV: a double blind, placebo controlled trial. J Clin Psychiatry 2000, 62:436-440.
47. Brietbart W, Rosenfeld B, Kaim M, et al.: A randomized, double-blind, placebo controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001, 161:411-420.
48. Rabkin JG, Wagner GJ, Rabkin R: A double-blind, placebo controlled trial of testosterone for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000, 57:141-147.
49. Rabkin JG, Ferrando SJ, Wagner GJ: DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology 2000, 25:53-68.
50. Piscitelli SC, Burstein AH, Chaitt D: Indinavir concentrations and St. John's wort. Lancet 2000, 355:547-548.